Seagen Inc.
171
19
33
86
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
26.9%
46 terminated/withdrawn out of 171 trials
65.2%
-21.4% vs industry average
7%
12 trials in Phase 3/4
66%
57 of 86 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (171)
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
Role: collaborator
Brentuximab Vedotin for Systemic Sclerosis
Role: collaborator
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Role: collaborator
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
Role: collaborator
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
Role: collaborator
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Role: collaborator
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Role: collaborator
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Role: collaborator
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
Role: collaborator
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Role: collaborator
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Role: collaborator
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Role: collaborator
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Role: collaborator
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Role: collaborator
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Role: collaborator
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Role: collaborator
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
Role: collaborator
Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
Role: collaborator
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
Role: collaborator
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
Role: collaborator